Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

S Popat, Y Barbachano, S Ashley, A Norton, M O'Brien - Lung Cancer, 2008 - Elsevier
BACKGROUND: Both docetaxel and erlotinib improve overall survival over best supportive
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …
被引用次数：17 相关文章

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

S Popat, Y Barbachano, S Ashley… - Lung cancer …, 2008 - pubmed.ncbi.nlm.nih.gov
Background Both docetaxel and erlotinib improve overall survival over best supportive care
in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) and …

[引用][C] Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

S POPAT, Y BARBACHANO, S ASHLEY… - Lung …, 2008 - pascal-francis.inist.fr
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung
cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

[引用][C] Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

S Popat, Y Barbachano, S Ashley, A Norton, M O'Brien - Lung Cancer, 2008 - cir.nii.ac.jp
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung
cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.

S Popat, Y Barbachano, S Ashley, A Norton… - Lung Cancer …, 2007 - europepmc.org
Background Both docetaxel and erlotinib improve overall survival over best supportive care
in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) and …

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

S Popat, Y Barbachano, S Ashley, A Norton, M O'Brien - Lung Cancer, 2008 - infona.pl
Both docetaxel and erlotinib improve overall survival over best supportive care in non-small
cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) and gefitinib (G) in …

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer

S Popat, Y Barbachano, S Ashley, A Norton… - Lung …, 2008 - lungcancerjournal.info
Background Both docetaxel and erlotinib improve overall survival over best supportive care
in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) and …